NCT02016911View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 12, 2013

Primary Completion Date

January 12, 2015

Study Completion Date

January 12, 2015

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

semaglutide

Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg

Trial Locations (6)

10034

Novo Nordisk Investigational Site, Prague

17000

Novo Nordisk Investigational Site, Prague

83101

Novo Nordisk Investigational Site, Bratislava

15-879

Novo Nordisk Investigational Site, Bialystok

02-507

Novo Nordisk Investigational Site, Warsaw

05-200

Novo Nordisk Investigational Site, Wołomin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY